Alcon Inc. must pay Sight Sciences Inc. $34 million after a federal jury in Delaware found its minimally invasive glaucoma surgery device infringes three patents.
The Hydrus Microstent—including its delivery system, instructions, and the method of implanting the device—infringes US Patent Nos. 8,287,482; 9,370,443; and 11,389,328, according to a verdict issued April 26 in the US District Court for the District of Delaware.
The jury rejected arguments Alcon and its Ivantis Inc. unit offered for invalidating the patents during the trial in Wilmington, Del.
Jurors awarded Sight Sciences $5.5 million in lost profits and $28.5 million as ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.